JP2011510667A - 軟骨変性に対する抗原結合性ポリペプチド - Google Patents

軟骨変性に対する抗原結合性ポリペプチド Download PDF

Info

Publication number
JP2011510667A
JP2011510667A JP2010545343A JP2010545343A JP2011510667A JP 2011510667 A JP2011510667 A JP 2011510667A JP 2010545343 A JP2010545343 A JP 2010545343A JP 2010545343 A JP2010545343 A JP 2010545343A JP 2011510667 A JP2011510667 A JP 2011510667A
Authority
JP
Japan
Prior art keywords
antigen
cartilage
binding polypeptide
esba105
intra
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010545343A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011510667A5 (cg-RX-API-DMAC10.html
Inventor
デイビッド ユレック，
ペーター リヒトレン，
Original Assignee
デレネックス セラピューティクス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デレネックス セラピューティクス アーゲー filed Critical デレネックス セラピューティクス アーゲー
Publication of JP2011510667A publication Critical patent/JP2011510667A/ja
Publication of JP2011510667A5 publication Critical patent/JP2011510667A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2010545343A 2008-02-05 2009-02-05 軟骨変性に対する抗原結合性ポリペプチド Pending JP2011510667A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2631708P 2008-02-05 2008-02-05
US8887608P 2008-08-14 2008-08-14
PCT/CH2009/000045 WO2009097704A1 (en) 2008-02-05 2009-02-05 Antigen-binding polypeptides against cartilage degeneration

Publications (2)

Publication Number Publication Date
JP2011510667A true JP2011510667A (ja) 2011-04-07
JP2011510667A5 JP2011510667A5 (cg-RX-API-DMAC10.html) 2013-01-24

Family

ID=40568129

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010545343A Pending JP2011510667A (ja) 2008-02-05 2009-02-05 軟骨変性に対する抗原結合性ポリペプチド

Country Status (10)

Country Link
US (1) US20110002927A1 (cg-RX-API-DMAC10.html)
EP (1) EP2240515A1 (cg-RX-API-DMAC10.html)
JP (1) JP2011510667A (cg-RX-API-DMAC10.html)
CN (1) CN101939335B (cg-RX-API-DMAC10.html)
AU (1) AU2009212079B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0907485A2 (cg-RX-API-DMAC10.html)
CA (1) CA2712965A1 (cg-RX-API-DMAC10.html)
IL (1) IL206720A0 (cg-RX-API-DMAC10.html)
RU (1) RU2010136988A (cg-RX-API-DMAC10.html)
WO (1) WO2009097704A1 (cg-RX-API-DMAC10.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015087839A1 (ja) * 2013-12-13 2015-06-18 Ｍｍｉｐマネジメント株式会社 関節軟骨イメージング組成物
JP2019514957A (ja) * 2016-05-06 2019-06-06 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 軟骨へのカプセル化薬剤の制御送達のための二成分型自己集合ゲル
US11672864B2 (en) 2010-09-24 2023-06-13 The Brigham And Women's Hospital, Inc. Nanostructured gels capable of controlled release of encapsulated agents

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104231086B (zh) * 2013-08-27 2019-12-13 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
CN113825495A (zh) 2018-10-11 2021-12-21 阿利维奥治疗学股份有限公司 用于智能释放的不可注射水凝胶调配物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131013A2 (en) * 2005-06-07 2006-12-14 Esbatech Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
ES2603399T3 (es) * 2006-07-10 2017-02-27 Esbatech, An Alcon Biomedical Research Unit Llc Anticuerpos scFv que atraviesan capas epiteliales y/o endoteliales

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131013A2 (en) * 2005-06-07 2006-12-14 Esbatech Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013030220; Ｊ．　Ａｎａｔ． Ｖｏｌ．１２２，　Ｎｏ．２, 1976, ｐｐ．３３５-３４７ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11672864B2 (en) 2010-09-24 2023-06-13 The Brigham And Women's Hospital, Inc. Nanostructured gels capable of controlled release of encapsulated agents
WO2015087839A1 (ja) * 2013-12-13 2015-06-18 Ｍｍｉｐマネジメント株式会社 関節軟骨イメージング組成物
US10143762B2 (en) 2013-12-13 2018-12-04 Mercury Assel Management Co., Ltd. Articular cartilage imaging composition
JP2019514957A (ja) * 2016-05-06 2019-06-06 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 軟骨へのカプセル化薬剤の制御送達のための二成分型自己集合ゲル
JP7169880B2 (ja) 2016-05-06 2022-11-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 軟骨へのカプセル化薬剤の制御送達のための二成分型自己集合ゲル

Also Published As

Publication number Publication date
AU2009212079A1 (en) 2009-08-13
IL206720A0 (en) 2010-12-30
RU2010136988A (ru) 2012-03-20
CA2712965A1 (en) 2009-08-13
EP2240515A1 (en) 2010-10-20
US20110002927A1 (en) 2011-01-06
CN101939335B (zh) 2015-02-11
BRPI0907485A2 (pt) 2015-08-04
WO2009097704A1 (en) 2009-08-13
AU2009212079B2 (en) 2012-08-30
CN101939335A (zh) 2011-01-05

Similar Documents

Publication Publication Date Title
Dinarello The IL-1 family of cytokines and receptors in rheumatic diseases
Ait-Oufella et al. Anticytokine immune therapy and atherothrombotic cardiovascular risk
US20240368268A1 (en) Method of modulating the activity of adrenomedullin in a subject in need of therapeutic intervention for organ dysfunction or organ failure associated with adrenomedullin (adm) activity by administering an anti-adrenomedullin (adm) antibody or an anti-adm fragment to the subject
Kimmerling et al. Sustained intra-articular delivery of IL-1RA from a thermally-responsive elastin-like polypeptide as a therapy for post-traumatic arthritis
KR102249078B1 (ko) 요법에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드
US9304127B2 (en) Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment for use in therapy
Liang et al. Blockade of tumor necrosis factor (TNF) receptor type 1-mediated TNF-α signaling protected Wistar rats from diet-induced obesity and insulin resistance
US10227405B2 (en) Methods of modulating the activity of adrenomedullin in a subject in need of regulation of fluid balance by administering an anti-adrenomedullin (ADM) antibody or an anti-ADM antibody fragment
AU2012338730B2 (en) Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
Urech et al. Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNFα single-chain Fv antibody (ESBA105) designed for local therapeutic use
Ruscitti et al. The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes
US20140322225A1 (en) Anti-Adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
Genevay et al. Influence of cytokine inhibitors on concentration and activity of MMP-1 and MMP-3 in disc herniation
CN101939335B (zh) 抗软骨退变的抗原结合多肽
Pasi et al. Novel multimeric IL-1 receptor antagonist for the treatment of rheumatoid arthritis
Galozzi et al. Development and role in therapy of canakinumab in adult-onset Still’s disease
Ursini et al. Infliximab and insulin resistance
Coll Therapeutic targeting of inflammasome signaling by blocking interleukin-1
JP7713983B2 (ja) カナキヌマブの使用
KR102649338B1 (ko) 세포 내 침투능을 갖는 항 stat3 이중특이 항체를 포함하는, 염증성 질환 치료용 약학적 조성물
Jones What's new in osteoarthritis?
Urech et al. Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF-α scFv (ESBA105) designed for local therapeutic use
Yokomi et al. POS1231 IL-6 INTERFERES WITH APOPTOSIS-INDUCTION OF RHEUMATOID ARTHRITIS FIBROBLAST-LIKE SYNOVIAL CELLS BY AFFECTING BCL-2 FAMILY OF PROTEINS
Gajdosik Brodalumab (AMG-827)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130913

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140502